Review





Similar Products

recombinant il 32b  (R&D Systems)
93
R&D Systems recombinant il 32b
Recombinant Il 32b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+32b/pm39211051-154-10-13?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
recombinant il 32b - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
il-32b  (R&D Systems)
90
R&D Systems il-32b
Il 32b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+32b/pm37456855-164-15-16?v=R%26D+Systems
Average 90 stars, based on 1 article reviews
il-32b - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
human il 32b r d systems  (R&D Systems)
93
R&D Systems human il 32b r d systems
Human Il 32b R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+32b/pm37456855-129-129-131?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
human il 32b r d systems - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
il 32b  (R&D Systems)
94
R&D Systems il 32b
Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
Il 32b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+32b/pm35143819-110-37-42?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
il 32b - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
copyright 2021 wolters kluwer h il 32b  (Wolters Kluwer Health)
86
Wolters Kluwer Health copyright 2021 wolters kluwer h il 32b
Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
Copyright 2021 Wolters Kluwer H Il 32b, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+32b/10__1097_slash_qad__0000000000002972-95-0-3?v=Wolters+Kluwer+Health
Average 86 stars, based on 1 article reviews
copyright 2021 wolters kluwer h il 32b - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
il-32b  (Federation of European Neuroscience Societies)
90
Federation of European Neuroscience Societies il-32b
Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
Il 32b, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+32b/pm24512848-10-7-15?v=Federation+of+European+Neuroscience+Societies
Average 90 stars, based on 1 article reviews
il-32b - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) IL-32b supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.

Journal: The Journal of investigative dermatology

Article Title: IL-32 Supports the Survival of Malignant T Cells in Cutaneous T-cell Lymphoma.

doi: 10.1016/j.jid.2022.01.009

Figure Lengend Snippet: Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) IL-32b supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.

Article Snippet: A total of 300,000e1,000,000 cells in 200 ml per well were cultured in round-bottom 96-well plates in the presence or absence of IL-2 (25 IU/ml, National Cancer Institute, Bethesda, MD), IL-32a (25 ng/ml; number 3040-IL-050, R&D Systems), IL-32b (25 ng/ml; number 6769-IL-025, R&D Systems), or IL-32g (25 ng/ml; number 4690-IL-025/CF, R&D Systems).

Techniques: High Throughput Screening Assay, Sequencing